Nitin KapoorProf. India

Nitin KapoorProf.
Dr. Nitin completed his DM & Post Doctoral Fellowship in Endocrinology at CMC, Vellore. He then completed his PhD research on clinical and genetic indicators of obesity from the University of Melbourne, Australia. He has been cited as among the top 2% of most influential researchers across the world by Stanford University, USA, in October 2023, 2024, and 2025. He has also been conferred with several awards, including the prestigious AR Seth gold medal by the Endocrine Society of India(2020), the Young Investigator Award by the Sri Lankan Endocrine Society(2019), Melbourne Research Scholarship (2016-20), The Tamil Nadu Dr. MGR University Gold Medal in Endocrinology(2015), AV Gandhi award for Excellence in Endocrine research (2014), The IJEM Award for Excellence in Endocrine writing(2014) and recently, he was also awarded the President’s award of appreciation by the Endocrine Society of India in Dec 2022 and the Best Mentor award of the year 2023-2024 by the Director, Christian Medical College, Vellore. He is the Editor of the current(June 2024) and the previous two editions of the book “A Practical Guide to Diabetes Mellitus”. He is also the section editor of the Obesity section of Endotext – The PubMed-indexed endocrine textbook. He has more than 400 PubMed-indexed peer-reviewed publications in national & international journals. He is an elected Executive committee member of The Endocrine Society of India (2022-28), All India Association for Advancing Research in Obesity (2022-25), The Endocrine Society of Tamil Nadu (2024-2026), and Honorary joint secretary of The Indian Society of Bone and Mineral Research(2024-2026).

21 MARCH

Time Session
08:30
10:00
[Indopacific Joint Symposium] Patient-Centred Diabetes Care in 2026
Addressing Psychological Burden and Enhancing Well-Being
Jung-Fu ChenTaiwan Moderator
Nitin KapoorIndia Moderator Changing Paradigms of Obesity Management in Asia-Oceania
  • Psychological Burden in Diabetes: Understanding Distress and Its Clinical Impact
    Ye-Fong DuTaiwan Speaker Psychological Burden in Diabetes: Understanding Distress and Its Clinical ImpactDiabetes distress represents the emotional burden arising from the daily demands of diabetes self-management and is conceptually distinct from major depressive disorder. Large-scale epidemiological studies indicate that 20–40% of people with diabetes experience clinically significant distress, making it one of the most prevalent psychological complications of diabetes. A growing body of longitudinal evidence demonstrates that diabetes distress is strongly associated with poor glycemic control, reduced treatment adherence, unhealthy dietary and physical activity patterns, and lower engagement with healthcare services. Importantly, diabetes distress predicts future deterioration in HbA1c independent of depressive symptoms, suggesting that it is a direct and modifiable determinant of metabolic outcomes rather than a mere emotional comorbidity. Interventional studies show that structured diabetes education, psychosocial counseling, and digital health–based self-management support can significantly reduce diabetes distress and are accompanied by improvements in glycemic control and self-efficacy. These findings highlight the bidirectional relationship between psychological burden and metabolic regulation. In the era of precision medicine and digital diabetes care, systematic screening and targeted management of diabetes distress should be integrated into routine clinical practice to optimize both psychological well-being and long-term cardiometabolic outcomes.
  • Enhancing Patient Experience in Diabetes Care: Communication and Empowerment Strategies
    Samuel ChenTaiwan Speaker Enhancing Patient Experience in Diabetes Care: Communication and Empowerment Strategies
  • What Does Person-Centred Diabetes Care Really Mean in 2026?
    Amandeep SinghIndia Speaker What Does Person-Centred Diabetes Care Really Mean in 2026?
  • Creating Happiness in the Diabetes Clinic: A Psychosocial Approach to Better Outcomes
    Sanjay KalraIndia Speaker Creating Happiness in the Diabetes Clinic: A Psychosocial Approach to Better Outcomes
103

22 MARCH

Time Session
11:00
12:30
[Symposium] Obesity (2)
Perspectives on Obesity in Asia-Oceania
Kathryn TanHong Kong, China Moderator Lipoprotein(a): What Endocrinologists Need to KnowLipoprotein(a) [Lp(a)] is a cholesterol-rich LDL-like particle with apolipoprotein(a) covalently linked to apolipoprotein B100 via a disulfide bond. Lp(a) is synthesized within the liver and there is a general inverse correlation between Lp(a) isoform size and plasma Lp(a) concentrations. About 90% of plasma Lp(a) concentration is genetically determined and plasma levels can modestly rise after menopause in women, and in conditions like hypothyroidism, nephrotic syndrome. It has been shown that elevated Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis. Although Lp(a) concentration does vary with ethnicity, relationships between Lp(a) concentration and ASCVD risk remain similar across different ethnic groups. Elevated Lp(a) is considered a cardiovascular risk-enhancing or amplification factor, and recent guidelines and consensus have increasingly recommended universal screening for Lp(a). There are as yet, no approved therapies for elevated Lp(a). Current management focuses on intensifying control of concurrent risk factors, particularly LDL-C, to reduce ASCVD risk. Amongst existing lipid-lowering drugs, only proprotein convertase subtilisin/kexin type 9 inhibitors can lower Lp(a) levels modestly. Emerging RNA-based and small-molecule therapeutics are under development and are showing promising Lp(a)-lowering effects up to 80-90%. Ongoing phase 3 cardiovascular outcomes trials will determine whether effectively lowering Lp(a) can translate to cardiovascular benefit.
101